Moneycontrol PRO
HomeNewsIndiaIndia crosses 100-crore-vaccination mark | The Everest is yet to be conquered

India crosses 100-crore-vaccination mark | The Everest is yet to be conquered

India crossed the 100-crore (one-billion) mark in administering COVID-19 vaccination doses on October 21. The challenge to fully inoculate the country’s large population lies ahead.

October 21, 2021 / 13:45 IST
Despite the hostile terrain, the northern state of Himachal Pradesh, where Malana is located, earlier this month became the first in India to administer at least one COVID-19 vaccine dose in all its adults. (Image: Reuters)

India, on October 21, achieved the significant milestone of vaccinating 100 crore people against COVID-19. While this is a credible and commendable achievement given the size of its population, the country is yet to fully inoculate a significant proportion of its people.

It took India 278 days to administer 100 crore jabs, with more than 50 percent of the population getting the first dose and over 21 percent having received both doses.

“Achieving the 1 billion vaccination mark in India is a remarkable feat,” said Chandrakant Lahariya, a Delhi based epidemiologist and public health expert. “This shows that if there is a will, the Indian healthcare system can deliver when required. While we should celebrate the milestone and the efforts of healthcare workers, we should also be mindful of the huge challenge ahead of vaccinating the remaining adult population.”

Overall, the progress of the vaccination drive has been good considering the size of our nation and the population, said Gautam Menon, professor at Ashoka University and an infectious disease and public policy expert. “The pace of vaccination has dipped in recent days to about 5-6 million from 9-10 million over the past few weeks, but the reason for this isn't clear. While 30 percent of the adult population has been fully vaccinated, a further 44 percent have only received one dose,” he added.

Data show that the pace of vaccination has not been consistent, pointing to the herculean task ahead for the administration to fully inoculate the population.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Dr Lahariya said the drop in the pace of vaccination could be a result of new beneficiaries or first dose takers not turning up in adequate numbers, with many of those due for a second dose waiting to complete their 12 week gap between jabs. The pace of vaccination picked up in September, so an uptick could again be seen after three months for second dose seekers. Policymakers should try to find out the reasons for vaccine hesitancy, which while it exists is less than originally thought, and address them at the earliest, he added.

“About 26 percent of the adult population is yet to be vaccinated with even one dose which remains a gap to be bridged,” Menon said. “I hope that these unvaccinated are yet to be reached out to and that this gap is not due to any significant hesitancy. Vaccination rates should be ramped up going forward to cover those awaiting the second dose and for the unvaccinated. In the longer term, the substantial below-18 population will likely need to be vaccinated, although vaccinating adults, who are more vulnerable to the disease, should remain our current priority.”

The 1 billion doses administered largely covers single doses, and the focus should now be accelerating second doses or fully inoculating the remaining population, said Deepak Saxena, epidemiologist and professor at the Indian Institute of Public Health, Gandhinagar.

Among states that have administered both doses, in absolute numbers, Maharashtra reports the most at 28.8 million, followed by Uttar Pradesh (27.8 million) and Gujarat (23.5 million). Union territories and smaller states lie at the bottom, a corollary of their having smaller populations.


Let’s take a look at where India stands in terms of vaccinating its population.

The United Arab Emirates has the most—85 percent of its people—fully vaccinated, according to Our World in Data as on October 19. The United States has fully inoculated 56 percent of its population, Brazil 50 percent and Germany 65 percent, while the share of people fully vaccinated in India is reported to be 20.6 percent.

It bears repeating that this landmark was achieved despite the challenges of a large population and people staying in remote areas. The efforts put in by healthcare workers and vaccinators in reaching the last mile has been commendable.


The way forward

“We need to carry out more sero-surveillance surveys to ensure that the antibodies developed are good enough to protect us. People who had been vaccinated early this year should have good enough titers (a measure of antibodies) to protect them. The government should now explore giving booster doses at least to the vulnerable, as most western countries have already started doing. The other hot topic is exploring mix-and-match of vaccines. So it would be a good time to do more research on the cocktail vaccinations and also consolidate our approach to boost the second dose,” Dr Saxena said.

We should also derive lessons for the future that a successful programme delivery requires coordinated action between policy formulation, administration, ensuring adequate supply and on-the -ground delivery, said Dr Lahariya. “The feat highlights this: if there is a political will, our health systems can deliver even in challenging times. These learnings can be useful for implementation of other health programmes in the country, which fall short due to these factors,” he added.

Moneycontrol News
first published: Oct 21, 2021 01:45 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347